Veraxa Biotech AG - Post de-SPAC SEC filings VRXA
Veraxa Biotech AG - Post de-SPAC has 56 filings in SEC EDGAR's recent list, going back to Jul 31, 2025. Its latest annual report, Form 20-F, was filed on Jun 16, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 15, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | Jun 16, 2026 | Dec 31, 2025 |
Showing 1 filing. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRXA (Nasdaq), VRXAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zurich
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2079109
- Former names
- Veraxa Biotech Holding AG (until Aug 13, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.